Skip to main content
Journal of the National Medical Association logoLink to Journal of the National Medical Association
letter
. 1980 May;72(5):453–457.

Malignant Hypertension Revisited: The Role of Bilateral Nephrectomy

Iluminado Cruz, Clive O Callender, Yvonne Cummings, Martin Dillard, Adrian Hosten, Joel Stevens
PMCID: PMC2552437  PMID: 6991710

Abstract

Hypertension is the leading cause of renal failure in this dialysis and transplant center. When malignant hypertension is encountered, the symptom complex of cachexia and failure to thrive highlights its clinical presentation. The courses of 32 black renal hypertensive patients studied retrospectively demonstrated this symptom complex as well as prolongation of survival, when bilateral nephrectomy and renal transplantation were used as definitive treatment.

Full text

PDF
453

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cruz I. A., Dillard M. G., Hosten A. O. Azotemic malignant hypertension: clinical course and survival with vigorous anti-hypertensive regimen and intermittent dialysis. Med Ann Dist Columbia. 1973 Apr;42(4):185–188. [PubMed] [Google Scholar]
  2. HARINGTON M., KINCAID-SMITH P., McMICHAEL J. Results of treatment in malignant hypertension: a seven-year experience in 94 cases. Br Med J. 1959 Nov 14;2(5158):969–980. doi: 10.1136/bmj.2.5158.969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. KINCAID-SMITH P., McMICHAEL J., MURPHY E. A. The clinical course and pathology of hypertension with papilloedema (malignant hypertension). Q J Med. 1958 Jan;27(105):117–153. [PubMed] [Google Scholar]
  4. Merrill J. P. Dialysis versus transplantation in the treatment of end-stage renal disease. Annu Rev Med. 1978;29:343–358. doi: 10.1146/annurev.me.29.020178.002015. [DOI] [PubMed] [Google Scholar]
  5. Perry H. M., Jr, Schroeder H. A., Catanzaro F. J., Moore-Jones D., Camel G. H. Studies on the control of hypertension. 8. Mortality, morbidity, and remissions during twelve years of intensive therapy. Circulation. 1966 Jun;33(6):958–972. doi: 10.1161/01.cir.33.6.958. [DOI] [PubMed] [Google Scholar]
  6. SCHOTTSTAEDT M. F., SOKOLOW M. The natural history and course of hypertension with papilledema (malignant hypertension). Am Heart J. 1953 Mar;45(3):331–362. doi: 10.1016/0002-8703(53)90147-1. [DOI] [PubMed] [Google Scholar]
  7. Woods J. W., Blythe W. B. Management of malignant hypertension complicated by renal insufficiency: further experience. Trans Am Clin Climatol Assoc. 1968;79:108–114. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES